InstalabLoading...
InstalabLoading...
Most people who carry this genetic variant learn about it only after a clot has already happened. That timing is unfortunate, because the risk has been quietly present since birth. Knowing your status before a clotting event lets you rethink choices that can multiply your odds: hormonal birth control, hormone replacement therapy, long-haul flights, surgery, and pregnancy planning.
A single test answers a question that routine bloodwork was never designed to ask. Standard coagulation panels look at how fast your blood clots in the moment. This test looks at whether your body is wired, from your DNA, to clot more aggressively across your whole life.
Factor II is another name for prothrombin, the protein your liver makes that gets converted into thrombin (the enzyme that drives clot formation). The most common inherited variant of this gene is called G20210A, a single-letter change in the DNA code. People who carry one copy of this variant produce slightly more prothrombin and generate more thrombin than non-carriers, which tilts their bloodstream toward forming clots.
The variant is one of the most common inherited clotting risk factors in people of European ancestry. It is fixed at birth and does not change with diet, age, or lifestyle. What changes is the company it keeps: how it interacts with hormones, surgery, cancer, pregnancy, and other clotting risks you accumulate over time.
The clearest signal from this variant is in the veins, specifically deep vein thrombosis (a clot in a leg or arm vein) and pulmonary embolism (a clot that travels to the lungs). Together these are called venous thromboembolism, or VTE.
People who carry one copy of the G20210A variant have roughly 2 to 4 times the risk of a first or recurrent VTE compared to non-carriers. In a study of 251 people with deep vein thrombosis, carriers also had a higher rate of repeat clots after the first event, even after stopping anticoagulation.
Risk multiplies sharply when the variant collides with other exposures. Women who carry G20210A and use oral contraceptives have roughly 16 times the risk of deep vein thrombosis compared to non-carrier non-users in a Italian case-control study. In cancer patients, a meta-analysis found the variant roughly doubles VTE risk.
Carrying both this variant and Factor V Leiden (another common clotting variant) raises the stakes further. In a combined analysis of nearly 94,000 people from FinnGen and the UK Biobank, double heterozygotes had VTE risk similar to people who carry two copies of Factor V Leiden, a configuration considered high-risk.
The variant has also been linked to clots in arteries, not just veins. A meta-analysis of inherited thrombophilia and ischemic stroke (a stroke caused by a blocked artery in the brain) found G20210A carriers had increased risk in adults. Two separate meta-analyses covering 3,586 cases and 6,440 controls reached the same conclusion in children and young adults.
In a case-control study of 79 young women with myocardial infarction (heart attack) and 381 controls, G20210A carriers had elevated risk of heart attack, and the risk became substantially higher when combined with other heart-disease risk factors such as smoking or high blood pressure.
A study of 290 women of reproductive age found the G20210A mutation was associated with elevated prothrombin activity, and the combination predicted thrombotic events with high accuracy. Combined with the roughly 16-fold deep vein thrombosis risk seen in pill users who carry the variant, this is the most actionable insight from a positive result for women: estrogen-containing contraception, hormone replacement, and pregnancy itself raise clotting risk in a way that interacts with this gene.
Because this is a genetic test, results come back as a genotype rather than a number on a sliding scale. Your two copies of the gene (one from each parent) are reported together. Most people who order this test will be non-carriers; the variant appears in roughly 2 to 4 percent of people of European descent and is rarer in other ancestries.
| Result | What It Means | Approximate VTE Risk |
|---|---|---|
| G/G (non-carrier) | You do not carry the variant. This is the most common result. | Baseline (the reference) |
| G/A (heterozygous) | You carry one copy of the variant. The most common form of a positive result. | About 2 to 4 times baseline |
| A/A (homozygous) | You carry two copies. Rare but high-risk. | Substantially higher than heterozygous, though precise estimates vary across studies |
Because the variant is fixed at birth, you do not retest to track your level. You test once, learn your status, and act on it for the rest of your life.
Unlike cholesterol or blood sugar, your genotype does not move. A single accurate result is your result for life. What does change over time is the context around your result: the medications you take, your surgical history, whether you become pregnant, whether you develop cancer, and how you travel. Each of these reshapes how much your variant matters at a given moment.
If you are a carrier, the trending you should care about is functional, not genetic. Periodic check-ins on overall coagulation status, especially before surgery, during pregnancy planning, or if you start a new hormone-containing medication, give your physician a baseline to compare against if a clot is ever suspected.
A positive result does not mean a clot is coming. Most carriers never develop one. It does mean you should treat clotting-amplifying exposures with more caution than the general population.
If you have already had an unexplained clot, a positive result helps explain why and informs how long you should stay on anticoagulation. A consultation with a hematologist is the right next step in that case.
Genetic results are far more stable than functional blood tests, but a few situations can produce confusing readouts:
Factor II Activity is best interpreted alongside these tests.